NovaBridge advances givastomig toward Phase III for NovaBridge stock

NovaBridge Biosciences (ISIN US44975P1030) is advancing its lead cancer drug givastomig toward a potential Phase III study by year-end 2026, according to Investing.com on September 10, 2026. The company is using givastomig in first-line gastric cancer studies while also developing VIS-101 in ophthalmology.

Phase III plans carry the story

Givastomig moved from a 17-patient Phase I asset in July 2025 toward a broader development program. Management said the drug is being tested with immunochemotherapy and is designed to target Claudin 18.2 with conditional 4-1BB activation.

The same September 10, 2026 conference update described Phase II enrollment in gastric cancer and plans for a more mature dataset at ESMO. The company is also evaluating givastomig in pancreatic ductal adenocarcinoma and biliary tract cancer, with early data expected in 2027.

Cash supports the development push

NovaBridge held USD 216.0 million in cash and investments as of June 30, 2026, including USD 191.0 million in cash and cash equivalents, according to Yahoo Finance in the August 20, 2026 earnings-call transcript. The balance sheet was described as debt-free, giving the company financial capacity while it plans a larger registrational study.

For the first half of 2026, NovaBridge reported a USD 37.9 million net loss, according to Scanx on September 18, 2026. That loss puts the development timetable and financing strategy alongside the clinical data as central variables for the stock.

Two programs shape the pipeline

NovaBridge owns 65.00 percent of Visara Therapeutics, which is developing VIS-101 for retinal disease. The Phase IIa program showed that 67.00 percent of patients did not require retreatment at six months and 50.00 percent did not require retreatment at nine months, according to the September 10, 2026 conference transcript.

NovaBridge stock had a market capitalization of USD 161.4 million on October 6, 2026, with a 52-week range of USD 1.31 to USD 6.79. The stock's valuation therefore remains closely tied to clinical execution, financing discipline and the ability of givastomig and VIS-101 to produce larger-study evidence.

Stock valuation and pipeline risk

The stock's market value and the company's USD 216.0 million cash position provide two different lenses on NovaBridge. Cash gives the pipeline time to advance, while the USD 37.9 million first-half loss shows why future trials require careful capital allocation.

NovaBridge's Nasdaq listing and its clinical-stage status leave regulatory and trial outcomes as major valuation variables. The company is targeting Phase III progress for givastomig by year-end 2026 and Phase III development for VIS-101 after its ongoing Phase II-B work.

What the next milestones mean

The next meaningful evidence point is the updated givastomig dataset described for ESMO in October 2026. A stronger response and progression-free survival profile could support the planned development path, while the larger study design will test whether the early signal holds across more patients.

The company also faces a practical test in ophthalmology. VIS-101 must preserve its durability profile in a Phase II-B study of about 100 patients before a global Phase III program can move forward in 2027.

NBP market context

NovaBridge Biosciences was trading at a USD 1.40 primary-market price on October 6, 2026, with a USD 1.36 prior close and a plus 2.94 percent daily change. The euro reference quotation from Lang & Schwarz was dormant on October 6, 2026 and did not provide a usable current euro price.

More news and analyses on NovaBridge Biosciences stock